Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Stock Performance

Shares of AVDL traded up $0.07 during mid-day trading on Friday, reaching $6.93. The company's stock had a trading volume of 657,756 shares, compared to its average volume of 796,493. The company has a current ratio of 2.72, a quick ratio of 3.65 and a debt-to-equity ratio of 2.11. Avadel Pharmaceuticals has a 1-year low of $1.05 and a 1-year high of $11.59. The business has a 50-day simple moving average of $3.91 and a two-hundred day simple moving average of $5.21. The stock has a market cap of $409.15 million, a P/E ratio of -3.04 and a beta of 1.51.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Rating) last posted its earnings results on Tuesday, August 9th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.60). During the same period last year, the business earned ($0.33) earnings per share. As a group, equities research analysts anticipate that Avadel Pharmaceuticals will post -1.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. SVB Leerink boosted their price objective on shares of Avadel Pharmaceuticals from $6.00 to $12.00 and gave the stock an "outperform" rating in a research report on Thursday. Stifel Nicolaus boosted their price objective on shares of Avadel Pharmaceuticals from $2.00 to $5.00 in a research report on Tuesday, July 19th. Needham & Company LLC boosted their price objective on shares of Avadel Pharmaceuticals from $6.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday. Oppenheimer cut their price objective on shares of Avadel Pharmaceuticals to $13.00 in a research report on Friday, May 27th. Finally, Jefferies Financial Group lowered shares of Avadel Pharmaceuticals from a "buy" rating to a "hold" rating and boosted their price objective for the stock from $6.00 to $8.00 in a research report on Wednesday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $10.29.

Insider Buying and Selling

In other Avadel Pharmaceuticals news, Director Eric J. Ende bought 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 31st. The shares were acquired at an average cost of $2.16 per share, with a total value of $32,400.00. Following the acquisition, the director now owns 114,900 shares of the company's stock, valued at $248,184. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Thomas S. Mchugh purchased 50,000 shares of Avadel Pharmaceuticals stock in a transaction that occurred on Friday, May 27th. The stock was acquired at an average cost of $2.14 per share, for a total transaction of $107,000.00. Following the purchase, the chief financial officer now directly owns 71,500 shares of the company's stock, valued at approximately $153,010. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Eric J. Ende purchased 15,000 shares of Avadel Pharmaceuticals stock in a transaction that occurred on Tuesday, May 31st. The stock was purchased at an average price of $2.16 per share, with a total value of $32,400.00. Following the completion of the purchase, the director now directly owns 114,900 shares in the company, valued at $248,184. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 75,000 shares of company stock valued at $155,400. 3.20% of the stock is owned by insiders.